Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 410Lung Neoplasms 261Small Cell Lung Carcinoma 75Colorectal Neoplasms 71Breast Neoplasms 52Ovarian Neoplasms 48Neoplasms 48Melanoma 48Pancreatic Neoplasms 45Neoplasm Metastasis 38Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 31Prostatic Neoplasms 28Head and Neck Neoplasms 27Esophageal Neoplasms 26Carcinoma, Renal Cell 26Endometrial Neoplasms 25Colonic Neoplasms 24Triple Negative Breast Neoplasms 23Uterine Cervical Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Hepatocellular 21Mesothelioma, Malignant 14Mesothelioma 14Sarcoma 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Diseases 13Liver Neoplasms 13Carcinoma, Transitional Cell 13Thyroid Neoplasms 12

Interventions

pembrolizumab 1cemiplimab 1Pemetrexed 1Cisplatin 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × Thoracic × 30 days × Clear all
NCT05420220 2026-05-28

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Completed
95 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06452277 2026-05-18

SOHO-02

Bayer

Phase 3 Recruiting
444 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT05099172 2026-05-13

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Bayer

Phase 1/2 Active not recruiting
370 enrolled 1 FDA
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06269133 2026-05-08

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Regeneron Pharmaceuticals

Active not recruiting
1,000 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡